Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors

Phase 1 Completed 28 enrolled University of Illinois at Chicago Millennium Pharmaceuticals, Inc. · collab

NaSingle-groupOpen-labelTreatment

Summary

This phase I trial using the EffTox design will evaluate activity and safety of alisertib, an Aurora A kinase inhibitor, when given in combination with the selective VEGFR inhibitor pazopanib in patients with advanced, previously treated non-hematologic solid tumors.

Timeline

Start: 2013-08-14
Primary completion: 2016-07-28
Completion: 2016-07-28

Publications

Shah HA, Fischer JH, Venepalli NK, Danciu OC, Christian S, Russell MJ, Liu LC, Zacny JP, Dudek AZ. Phase I Study of Aurora A Kinase Inhibitor Alisertib (MLN8237) in Combination With Selective VEGFR Inhibitor Pazopanib for Therapy of Advanced Solid Tumors. Am J Clin Oncol. 2019 May;42(5):413-420. doi: 10.1097/COC.0000000000000543.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Alisertib	Small molecule	20 mg	Oral
Subject	Pazopanib	Small molecule	600 mg	Oral

Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors

Summary

Timeline

Publications

Drugs

Indications